National News
AtriCure to Participate at the Canaccord Genuity 39th Annual Growth Conference
07.17.2019
MASON, Ohio --(BUSINESS WIRE)--Jul. 17, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Canaccord Genuity 39 th AnnualAtriCure to Announce Second Quarter 2019 Financial Results
07.10.2019
MASON, Ohio --(BUSINESS WIRE)--Jul. 10, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2019 financial results on Tuesday, July 30, 2019 .AtriCure Reports First Quarter 2019 Financial Results
04.25.2019
Worldwide revenue of $54.0 million – an increase of 14.8% year over year U.S. revenue of $43.0 million – an increase of 11.9% year over year International revenue of $11.0 million – an increase of 28.1% year over year MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2019-- AtriCure, Inc.AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart
04.23.2019
The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation MASON, Ohio --(BUSINESS WIRE)--Apr. 23, 2019-- AtriCure, Inc.AtriCure to Announce First Quarter 2019 Financial Results
04.04.2019
MASON, Ohio --(BUSINESS WIRE)--Apr. 4, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019 .AtriCure to Present at the Needham & Company’s 18th Annual Healthcare Conference
04.01.2019
MASON, Ohio --(BUSINESS WIRE)--Apr. 1, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Needham & Company’s 18 th Annual Healthcare Conference in NewAtriCure Reports Fourth Quarter and Full Year 2018 Financial Results
02.28.2019
2018 Worldwide revenue of $201 .6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162 .1 million – an increase of 17.2% year over year 2018 International revenue of $39 .5 million – an increase of 8.7% year over year MASON, Ohio --(BUSINESS WIRE)--Feb. 28, 2019-- AtriCure, Inc.AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States
02.19.2019
Endorsement complements the company’s ongoing commitment to physician education MASON, Ohio --(BUSINESS WIRE)--Feb. 19, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that TheAtriCure Announces Launch of the cryoICE® cryoSPHERE™ Probe
02.12.2019
cryoSPHERE probe launched in United States , designed exclusively for post-operative pain block MASON, Ohio --(BUSINESS WIRE)--Feb. 12, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announcedAtriCure Announces the First Patient Enrolled in the ICE-AFIB™ Clinical Trial
02.05.2019
Trial will evaluate the safety and effectiveness of AtriCure’s cryoICE ® Ablation System for the treatment of persistent and long-standing persistent atrial fibrillation in open concomitant cardiac surgery MASON, Ohio --(BUSINESS WIRE)--Feb. 5, 2019-- AtriCure, Inc.International News
AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
08.28.2018
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio --(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc.AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
06.05.2018
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes...AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
04.25.2017
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced itAtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
03.14.2017
MASON, Ohio --(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for theAtriCure Announces Approval for the cryoICE™ Platform in Japan
11.01.2016
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio --(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, todayAtriCure Receives CE Mark for the AtriClip® PRO2 Device
06.29.2016
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio --(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator inAtriCure Announces Approval for the AtriClip in Japan
01.19.2016
Approval opens up a new market for the most widely implanted left atrial appendage occlusion device in the world WEST CHESTER, Ohio --(BUSINESS WIRE)--Jan. 19, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA)In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
10.01.2013
AMSTERDAM, Netherlands --(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. ( Nasdaq: ATRC ), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training programPromising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
06.18.2013
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE --(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s